MetaCap

Dare Bioscience (DARE) vs Phio Pharmaceuticals (PHIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Phio Pharmaceuticals (PHIO) has outperformed Dare Bioscience (DARE) over the past year, losing 41.4% versus a loss of 75.8%. Over five years, DARE leads with a -98.1% price change compared with -99.6% for PHIO. Dare Bioscience is the larger company by market cap ($8.0 million vs $7.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DARE-75.75%PHIO-41.43%
+103%+9%-84%
Nov 21, 20251 yearNov 20, 2026
DARE-97.97%PHIO-99.56%
+80%-14%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DARE versus PHIO key metrics
MetricDAREPHIO
Share price$0.4074$0.656
Market cap$8.01M$7.84M
1-day change-9.87%-8.25%
YTD return-78.89%-37.52%
1-year return-75.75%-41.43%
5-year return-98.10%-99.56%
EPS (TTM)$-0.61$-1.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.03M—
Revenue growth (YoY)+10429.36%—
Net income (latest FY)$-13.40M$-8.70M
Gross margin71.29%—
Operating margin-1315.51%—
Net margin-1300.66%—
52-week high$3.78$1.88
52-week low$0.406$0.6395
Distance from 52-week high-89.22%-65.11%
Analyst consensusnonenone
Avg. price target upside+1944.67%+2034.15%
Average volume242.39K106.09K
Shares outstanding19.67M11.95M
Employees216
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PHIO has outperformed DARE by 34.3 percentage points over the past year.

About Dare Bioscience

DARE stock →

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Phio Pharmaceuticals

PHIO stock →

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

DARE vs PHIO FAQ

Which is bigger, Dare Bioscience or Phio Pharmaceuticals?

Dare Bioscience (DARE) is larger, with a market capitalization of $8.01M compared with $7.84M for Phio Pharmaceuticals (PHIO).

Which stock has performed better over the past year, DARE or PHIO?

PHIO returned -41.43% over the past 12 months, compared with -75.75% for DARE (price return, excluding dividends). Past performance does not predict future results.

Are Dare Bioscience and Phio Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons